Eli Lilly has introduced a groundbreaking medication, Mounjaro, also known as tirzepatide, aimed at combating obesity and type 2 diabetes. This once-weekly injectable targets two critical hormone receptors—GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1)—known for their role in controlling appetite and regulating blood sugar levels.
Clinical trials, including the highly regarded SURMOUNT-1 study, have showcased Mounjaro’s potential. Participants in the trial experienced significant weight loss, with some shedding as much as 22.5% of their body weight over a 72-week period. The medication helps by reducing hunger, improving insulin sensitivity, and enhancing blood sugar management.
Mounjaro is prescribed alongside a low-calorie diet and increased physical activity for adults with a Body Mass Index (BMI) of 30 or higher (classified as obesity) or 27 or higher (with obesity-related conditions). Its dual benefits make it a promising option for individuals battling weight and sugar-level challenges.
With its innovative mechanism of action and encouraging trial results, Mounjaro represents a significant step forward in addressing the growing global obesity and diabetes epidemic.
